Catalent gains over 11% and rebound from bottom 🔔

6:13 PM 15 November 2023

Catalent (CTLT.US) shares gain over 11% after publishing preliminary results for the first quarter of the fiscal year 2023/2024 and providing forecasts for the entire year. The company's stock price is rising despite a record loss recorded in the ended period.

Financial Summary

  • Net revenue of $982 million, a decrease of 3.9% year-over-year.

    • Biologics net revenue: $447 million, a 15% decrease year-over-year, above the estimated $426.9 million.
    • Net revenue from pharmaceuticals and consumer health: increased by 7.2% year-over-year, to $535 million.
  • Net loss of $715 million, including non-cash write-downs of the company's value amounting to $700 million.

  • Adjusted EBITDA of $115 million, a decrease of 38% year-over-year.

Forecasts for the entire fiscal year:

  • Net revenue: $4.3 - $4.5 billion.
  • Adjusted EBITDA: $680 - $760 million.
  • Net profit: $113 - $175 million.

In their commentary, the management emphasized Catalent's strategic achievements, including the strategic review initiated in August and changes in the board after a settlement with Elliott Investment Management. Despite these challenges, Catalent expects that the majority of its pre-filled syringe production capacities until 2026 will be fully booked in the short period, due to high demand for new weight-loss drugs from Danish drugmaker Novo Nordisk's Wegovy.

Catalent (CTLT.US) shares are gaining over 11% in today's trading. The increases are driven by optimistic forecasts and positive management sentiment. However, the company's recent problems have pushed its stock price to multi-year lows this year. The current rebound is still a fraction of the share price at the peak of the pandemic bull market, at $140 per share. The current increase is capped by levels of $46 and $51, and breaking through these levels could indicate a breakout from consolidation. Source: xStation 5

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits